2024 Rain oncology stock - Most recently, on Monday, November 21st, Franklin M. Berger bought 45,000 shares of Rain Oncology stock. The stock was acquired at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the transaction, the director now directly owns 928,207 shares of the company's stock, valued at $7,240,014.60.

 
Stockholder / Stock options: Rain Therapeutics; Advisory / Consultancy: Chair of Scientific Advisory. Board for Rain Therapeutics; Honoraria (self): Guardant .... Rain oncology stock

On average, Wall Street analysts predict. that Rain Oncology's share price could reach $1.33 by Sep 18, 2024. The average Rain Oncology stock price prediction forecasts a potential upside of 22.29% from the current RAIN share price of $1.09.Nov 9, 2023 · NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing ... 31 Jan 2023 ... Roth Capital Partners renewed coverage of Rain Oncology (Rain Oncology Stock Quote, Charts, News, Analysts, Financials NASDAQ:RAIN) on ...Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, …1.0900. +0.0200. +1.87%. Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 ...20 Jul 2023 ... In response to the announcement, Rain's stock price substantially dropped from $9.93 per share to $1.22 per share, eliminating approximately ...Dec 29, 2022 · Rain Therapeutics. NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology ... RAIN News Today | Why did Rain Oncology stock go up today? S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. 12 crew members are missing, 1 dead after a cargo ship sinks off a Greek island in stormy seas. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) Turned down for a loan, business owners look to …WebRain Oncology Inc (RAIN) Stock Price & News - Google Finance Home RAIN • NASDAQ Rain Oncology Inc Follow Share $1.04 After Hours: $1.04 (0.00%) 0.00 Closed: Nov 29, 4:02:15 PM GMT-5 ·...Rain Oncology last announced its earnings data on November 9th, 2023. The reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. Rain Oncology has generated ($2.06) earnings per share over the last year (($2.06) diluted earnings per share).Y-mAbs Therapeutics, Inc. (Y-mAbs), is a state-of-the-art, late-stage clinical, global biopharmaceutical company that is focused on the research and development of innovative antibody-based products under investigation using a range of cutting-edge technologies, licensed from one of the largest and most prestigious cancer-care …Stock Quote & Chart. Historical Price Lookup. ... Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR ... The offer is just the latest example of Concentra hoping to snap up a troubled biotech this year, after a reach out to Rain Oncology last month. Tang has already scored success when Concentra used ...Rain Oncology is a clinical-stage company focusing on research and development of innovative therapies for cancer patients. Rain Oncology provides a ...In the previous week, Rain Oncology had 18 more articles in the media than Celularity. MarketBeat recorded 21 mentions for Rain Oncology and 3 mentions for Celularity. Rain Oncology's average media sentiment score of 0.63 beat Celularity's score of -0.07 indicating that Celularity is being referred to more favorably in the media.RAIN ONCOLOGY INC RAIN, 2023-11-28 15:15:03 UTC, -0.8998, 6.2198, 1500000. RAIN ... Stock Lookup. Enter stock name: use * for wildcard.Company's Cash Reserves of $452.6 Million Expected to Fund Operations Until Mid-2026. Find the latest Kura Oncology, Inc. (KURA) stock quote, history, news and other vital information to help you ...Check out other analyst stock ratings. H.C. Wainwright On Rain Oncology. Analyst Mitchell Kapoor downgraded the rating on the stock to Neutral. “Since LPS harbors the highest prevalence of MDM2 ...Complete Rain Oncology Inc. stock information by Barron's. View real-time RAIN stock price and news, along with industry-best analysis. Rain Oncology Inc (RAIN) stock is down -87.44% while the S&P 500 has risen 0.1% as of 11:09 AM on Monday, May 22. RAIN is down -$8.68 from the previous closing price of $9.93 on volume of 16,197,454 shares. Over the past year the S&P 500 is higher by 5.60% while RAIN is down -51.92%. RAIN lost -$2.61 per share in the over the last 12 months.NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC …3 analysts have issued 1 year price objectives for Surface Oncology's stock. Their SURF share price targets range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 320.6% from the stock's current price. View analysts price targets for SURF or view …In the previous week, Rain Oncology had 18 more articles in the media than Celularity. MarketBeat recorded 21 mentions for Rain Oncology and 3 mentions for Celularity. Rain Oncology's average media sentiment score of 0.63 beat Celularity's score of -0.07 indicating that Celularity is being referred to more favorably in the media.WebRain Oncology Inc (RAIN) Stock Price & News - Google Finance Home RAIN • NASDAQ Rain Oncology Inc Follow Share $1.04 After Hours: $1.04 (0.00%) 0.00 Closed: Nov 29, 4:02:15 PM GMT-5 ·...Stock Quote & Chart. Historical Price Lookup. ... Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR ... 23 May 2023 ... In the last 3 months, 8 analysts have offered 12-month price targets for Rain Oncology. The company has an average price target of $10.91 with a ...The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.1 Aug 2023 ... Stocks; ›; ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities ...Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass" and the word λόγος (logos), meaning "study".Cancer survival has ...Company's Cash Reserves of $452.6 Million Expected to Fund Operations Until Mid-2026. Find the latest Kura Oncology, Inc. (KURA) stock quote, history, news and other vital information to help you ...A high-level overview of Rain Oncology Inc. (RAIN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Rain Oncology ( NASDAQ: RAIN) has received an acquisition proposal from Concentra Biosciences, an affiliate of Tang Capital Partners, for $1.25/share in cash. The clinical-stage micro-cap cancer ...4 Aug 2023 ... NEW YORK, Aug. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the ...Employment: Rain Oncology. Leadership: Rain Oncology. Stock and Other Ownership Interests: Rain Oncology. Consulting or Advisory Role: GreenPeptide, AstraZeneca, Roche/Genentech, Rain Oncology, Blueprint Medicines, Guardant Health. Patents, Royalties, Other Intellectual Property: Licensing fees for patent from Rain …WebAs of November 3, 2023, Rain had approximately 36.4 million shares of common stock outstanding. About Rain Oncology Inc. Rain Oncology Inc. is a precision oncology company developing therapies ...1 Aug 2023 ... Stocks; ›; ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities ...US75082Q1058. Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for …This one-day volume growth resulted in a record-breaking increase of 210%, as compared to the 65-Day Volume Moving Average. RAIN's total volume now sits at 584.3K. The -1.89% price change was insignificant, leaving RAIN's price at $1.04. This volume move could indicate a change in trend, and may be a buy signal for investors. A.I.dvisor found 35 …RAIN News Today | Why did Rain Oncology stock go up today? S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. 12 crew members are missing, 1 dead after a cargo ship sinks off a Greek island in stormy seas. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) Turned down for a loan, business owners look to …Web16 Oct 2023 ... Rain's shares had previously been riding far higher than that, ranging between $7 and $10 apiece for the first four months of the year, until ...Insiders who bought Rain Oncology Inc. (NASDAQ:RAIN) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$54m as a result of the stock's 21% gain ...NEWARK, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the first quarter ...Novartis, Pfizer, EMD-Serono , Sanofi Oncology, Janssen Oncology, Ignyta (now Roche), Roche/ ... Shareholder / Stockholder / Stock options: Rain Therapeutics; ...Nanopore design. The concept of nanopore sequencing emerged in the 1980s and was realized through a series of technical advances in both the nanopore and the associated motor protein 1,4,5,6,7,8 ...Rain Oncology is latest troubled biotech to receive acquisition offer from Concentra. By James Waldron Oct 16, 2023 10:20am. mergers and acquisitions Tang Capital Partners Deals. Five months after ...US75082Q1058. Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for …Oct 16, 2023. NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.The average price target is $1.33 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 20.91% change from the last ...According to the issued ratings of 12 analysts in the last year, the consensus rating for Rain Oncology stock is Hold based on the current 10 hold ratings and 2 buy ratings for RAIN. The average twelve-month price prediction for Rain Oncology is $17.00 with a high price target of $24.00 and a low price target of $11.00.Web4 Aug 2023 ... NEW YORK, Aug. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the ...WHY: NEW YORK, NY - (NewMediaWire) - August 27, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the “Class Period”), of the important September 12, 2023 lead plaintiff deadline. SO WHAT: If …7 brokerages have issued 1 year price targets for ALX Oncology's stock. Their ALXO share price targets range from $10.00 to $34.00. On average, they anticipate the company's stock price to reach $20.42 in the next year. This suggests a possible upside of 154.9% from the stock's current price. View analysts price targets for ALXO or view …Company's Cash Reserves of $452.6 Million Expected to Fund Operations Until Mid-2026. Find the latest Kura Oncology, Inc. (KURA) stock quote, history, news and other vital information to help you ...Nov 27, 2023 · Analyst Recommendations on Rain Oncology Inc. Citigroup Trims Rain Oncology's Price Target to $1 From 1.50, Keeps Neutral Rating. Sep. 18. MT. Mizuho Downgrades Rain Oncology to Neutral From Buy, Adjusts Price Target to $1 From $17. Jun. 05. MT. EF Hutton Cuts Rain Oncology's Price Target to $2 From $5, Maintains Hold Rating. NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock.Dec 29, 2022. NEWARK, Calif., December 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will change its name to Rain Oncology ... The offer is just the latest example of Concentra hoping to snap up a troubled biotech this year, after a reach out to Rain Oncology last month. Tang has already scored success when Concentra used ...Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting …WebAug 10, 2023. NEWARK, Calif., August 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. “Rain has been aggressively pursuing a multitude of opportunities as we seek to leverage our clinical execution capabilities and strong cash position to add value to our ...Debtor Name Clovis Oncology UK Limited Petition Date December 11, 2022 Case Number 22-11294 Debtor Name Clovis Oncology Ireland Limited Petition Date December 11, 2022 Info Center. 888.391.2243 (U.S./Canada Toll-Free) 646.440.4352 (International) LIVE ...Rain Oncology is a late-stage oncology company specializing in precision oncology by targeting oncogenic drivers. Click here to see why the stock is a speculative buy.According to the issued ratings of 12 analysts in the last year, the consensus rating for Rain Oncology stock is Hold based on the current 10 hold ratings and 2 buy ratings for RAIN. The average twelve-month price prediction for Rain Oncology is $17.00 with a high price target of $24.00 and a low price target of $11.00.Web1.0900. +0.0200. +1.87%. Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 ...WebRain Oncology stock plummets on late-stage cancer drug results - San Francisco Business Times bizjournals.com 1 Like Comment Share Copy; LinkedIn; Facebook; Twitter; To view ...Coming off stock drops following safety concerns over its recently approved eye injection Syfovre--which turned out to be related to the needle used to deliver the medicine, ... Rain Oncology is laying off 65% of its staff, including its chief medical officer. This news came one week after the company's lead candidate, ...Get Rain Oncology Inc (RAIN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsWebOverview MDM2 gene CN of ≥8 Patients enrolled based on local NGS for CN, centrally confirmed by Rain's diagnostic partner, Tempus Evaluable tumor types included: lung, …NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds ...Apr 18, 2023 · Rain Oncology Inc (RAIN) stock is trading at $7.36 as of 1:33 PM on Tuesday, Apr 18, a loss of -$0.08, or -1.08% from the previous closing price of $7.44. The stock has traded between $7.20 and $7.45 so far today. Volume today is less active than usual. Everyone has a different outlook on rain. If you have somewhere to go or are already out and about, it can be a major inconvenience — especially if you’re stranded without an umbrella.NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology... – Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 – – Phase 3 MANTRA topline data expected earlier than... US75082Q1058. Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for …23 May 2023 ... In the last 3 months, 8 analysts have offered 12-month price targets for Rain Oncology. The company has an average price target of $10.91 with a ...Rain Oncology Inc. Common Stock (RAIN) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is...Mar 9, 2023 · NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with its product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the fourth ... NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock.PFS (Primary): Approximately 105 events by blinded central review to trigger primary analysis. OS, ORR, DCR, DOR. Safety. TP53. Overview. MDM2 gene CN of ≥8. Patients enrolled based on local NGS for CN, centrally confirmed by Rain's diagnostic partner, Tempus. Evaluable tumor types included: lung, breast, biliary, pancreatic and other select ...Rain oncology stock

Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc.,.... Rain oncology stock

rain oncology stock

Non-cash stock-based compensation expense included in G&A expenses were approximately $0.3 million and $1.1 million for the three months and year ended December 31, 2022, respectively, as compared ...We would like to show you a description here but the site won’t allow us.1 Mar 2023 ... ... stock market cnbc awaaz,union budget 2023 ... Rain Industries Stock Analysis | Rain Industries Latest News Today | Share Analysis Business Model.Rain Oncology Inc. Common Stock (RAIN) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is... May 22, 2023. NEWARK, Calif., May 22, 2023 – Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and ...Success is Achieved Together. Biosimulation can reduce the size of and cost of human trials, the most expensive and time-consuming part of drug development. In some cases, we can eliminate certain human trials completely. More than 2,000 customers worldwide choose us as their partner for biosimulation software and technology-driven services.Rain Oncology Inc's stock momentum and predictability metrics also paint a bleak picture. The stock's RSI 5 Day, RSI 9 Day, and RSI 14 Day are 27.25, 30.15, and 30.19 respectively, indicating a ...WebRichard S. Pzena’s Pzena Investment Management is the biggest stakeholder of the company, with 3.86 million shares worth $277.7 million. Like Moderna, Inc. (NASDAQ:MRNA), BeiGene, Ltd. (NASDAQ ...Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass" and the word λόγος (logos), meaning "study".Cancer survival has ...Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28.Stock analysis for Rain Oncology Inc (RAIN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Nov 22, 2023 · The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California. Company Overview. Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than ...1.0900. +0.0200. +1.87%. Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 ...US75082Q1058. Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA. Show more.WebWhat is the target price for Rain Oncology (RAIN) stock? The latest price target for Rain Oncology ( NASDAQ: RAIN) was reported by Citigroup on Monday, September 18, 2023. The analyst firm set a ... May 23, 2023 · RAIN Price Action: Shares of Rain Oncology were down 1.64% to $1.20 at the time of publishing Tuesday, according to Benzinga Pro. Photo: Shutterstock SHARE THIS POST The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.WebMar 13, 2023 · 1.0900. +0.0200. +1.87%. Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 ... WHY: NEW YORK, NY - (NewMediaWire) - August 27, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the “Class Period”), of the important September 12, 2023 lead plaintiff deadline. SO WHAT: If …When it rains, most flies hide in any small sheltered spot where they are protected and out of the rain. Some tiny or very large types of flies may continue to fly. According to The Straight Dope, flies shelter under leaves, in crevices or ...US75082Q1058. Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA. Show more.WebEvents. News & press releases. Investors. Overview. Stock Information. Analyst Coverage. Stock Quote & Chart. Historical Price Lookup. Investment Calculator.Get the latest Rain Oncology Inc (RAIN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. As of November 3, 2023, Rain had approximately 36.4 million shares of common stock outstanding. About Rain Oncology Inc. Rain Oncology Inc. is a precision oncology company developing therapies ...WebThe number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of ...WebRain Oncology. stock last closed at $1.11, up 5.71% from the previous day, and has decreased 86.09% in one year. It has underperformed other stocks in the Biotechnology industry by 0.59 percentage points. Rain Oncology stock is currently +35.37% from its 52-week low of $0.82, and -92.33% from its 52-week high of $14.48.At …WebRain Oncology Inc (RAIN) Stock Price & News - Google Finance Home RAIN • NASDAQ Rain Oncology Inc Follow Share $1.04 After Hours: $1.04 (0.00%) 0.00 Closed: Nov 29, 4:02:15 PM GMT-5 ·...According to the issued ratings of 12 analysts in the last year, the consensus rating for Rain Oncology stock is Hold based on the current 10 hold ratings and 2 buy ratings for RAIN. The average twelve-month price prediction for Rain Oncology is $17.00 with a high price target of $24.00 and a low price target of $11.00.WebBrowse 28,070 authentic oncology stock photos, high-res images, and pictures, or explore additional cancer or oncologist stock images to find the right photo at the right size and resolution for your project. Browse Getty Images' premium collection of high-quality, authentic Oncology stock photos, royalty-free images, and pictures.Cardiff Oncology is a prime takeover target heading into 2022. The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. Four ...Nov 22, 2023 · Which Rain Oncology insiders have been buying company stock? The following insiders have purchased RAIN shares in the last 24 months: Aaron I Davis ($5,667,995.96), Bvf Partners L P/Il ($9,971,387.14), Franklin M Berger ($351,000.00), and Kevin C Tang ($1,179,304.12). Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting …WebMay 11, 2023 · NEWARK, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the first quarter ... Company Overview. Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than ...11 Aug 2023 ... Analyst Jason Zemansky thinks Kura Oncology could be a winner in blood cancer treatment, believing the stock could nearly triple in value.Jun 21, 2023 · NEW YORK, June 21, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rain Oncology Inc.:. On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million shares priced at $17.00. Analyst Recommendations on Rain Oncology Inc. Citigroup Trims Rain Oncology's Price Target to $1 From 1.50, Keeps Neutral Rating. Sep. 18. MT. Mizuho Downgrades Rain Oncology to Neutral From Buy, Adjusts Price Target to $1 From $17. Jun. 05. MT. EF Hutton Cuts Rain Oncology's Price Target to $2 From $5, Maintains Hold Rating.November 22, 2023. $1.07. 31,967. 1:1. $1.09. $1.09. $1.06. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits …Rain Oncology (NASDAQ: RAIN) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company’s ...Stock Quote & Chart. Historical Price Lookup. ... Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR ...Showing 10 out of 25 companies. Daiichi Sankyo Co Ltd, Takeda Pharmaceutical Co Ltd, Chugai Pharmaceutical Co Ltd, Astellas Pharma Inc, and Otsuka Holdings Co Ltd are the top 5 pharma companies in Japan by market capitalization (as of Mar 31, 2023). Comprehensively, the top 10 companies had a total market cap of $265,509 million (as of …Insiders who bought Rain Oncology Inc. (NASDAQ:RAIN) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$54m as a result of the stock's 21% gain ...Jun 21, 2023 · NEW YORK, June 21, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rain Oncology Inc.:. On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million shares priced at $17.00. Rain Oncology Inc ( RAIN) is down -3.97%% today. RAIN has an Overall Score of 52. Find out what this means to you and get the rest of the rankings on RAIN! See Full RAIN Report. RAIN stock closed at $1.26 and is down -$0.05 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only ...Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer. We are on a journey to shut down one of cancer’s most commonly mutated signaling cascades, the RAS/MAPK pathway, which affects approximately 5.5 million lives each year worldwide. Our promising pipeline targets the RAS/MAPK pathway at virtually every turn, …1. Introduction. Driven by many advances in nanomedicine, over the last few decades, there has been significant growth in the research and development of drug delivery devices in the form of polymeric nanoparticles, liposomes, and micelles. (1) The success of these nanocarriers largely depends on the choice of appropriate design parameters to ...3 analysts have issued 1 year price objectives for Surface Oncology's stock. Their SURF share price targets range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 320.6% from the stock's current price. View analysts price targets for SURF or view …Nov 9, 2023 · NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing ... Rain Oncology Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:58 p.m. EST Delayed quote $ 1.1100 0.00 0.00% After Hours Volume: 1.31K Advanced Charting... About Rain Oncology Inc. Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28.WebDec 1, 2023 · View Rain Oncology Inc RAIN investment & stock information. Get the latest Rain Oncology Inc RAIN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Rain Therapeutics. NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology ...Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28.ETFs & Funds. A high-level overview of Rain Oncology Inc. (RAIN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading …Rain Oncology Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:58 p.m. EST Delayed quote $ 1.1100 0.00 0.00% After Hours Volume: 1.31K Advanced Charting...Stock Price Forecast The 4 analysts offering 12-month price forecasts for Rain Oncology Inc have a median target of 1.38, with a high estimate of 2.00 and a low estimate of 1.00.WebDec 29, 2022 · The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology. NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will change its name to Rain Oncology Inc. effective ...Richard S. Pzena’s Pzena Investment Management is the biggest stakeholder of the company, with 3.86 million shares worth $277.7 million. Like Moderna, Inc. (NASDAQ:MRNA), BeiGene, Ltd. (NASDAQ ...At Yahoo Finance, you get free stock quotes, the latest news, portfolio management resources, international market data, social interaction and mortgage rates to help you manage your financial life.. Templeton global income fund